Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-2024
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Immune Checkpoint Inhibition in Head and Neck Cancer

Frontiers in Oncology
Cancer ResearchOncology
2018English

A Clinical Analysis of Head and Neck Cancer in Young Adults

JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY
2015English

mTOR Co-Targeting Strategies for Head and Neck Cancer Therapy

Cancer and Metastasis Reviews
Cancer ResearchOncology
2017English

Impact of HPV Infection on the Clinical Outcome of P-Cair Trial in Head and Neck Cancer

European Archives of Oto-Rhino-Laryngology
MedicineOtorhinolaryngology
2010English

Mammalian Target of Rapamycin (mTOR) Inhibition in Advanced Bronchial Carcinoids

European Oncology and Haematology
OncologyHematology
2015English

Evaluation of a Knowledge-Based Planning Model for Head and Neck Cancer Patients Treated in the Setting of a Clinical Trial

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

Inhibition of Glucosylceramide Synthase Sensitizes Head and Neck Cancer to Cisplatin

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

Clinical Significance of Early Detection of Esophageal Cancer in Patients With Head and Neck Cancer

Gut and Liver
HepatologyGastroenterology
2015English

A Comparative Immunofluorescence Analysis of Three Clinical-Stage Antibodies in Head and Neck Cancer

Head & Neck Oncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy